The PROstate Cancer Registry in Large Patient Population AIMed to Assess Efficacy in Germline Testing (PROCLAIM) Study

The PROCLAIM study determined the prevalence of pathogenic germline variants (PGVs) and their impact on treatment and management in a diverse cohort of patients with prostate cancer. The findings suggest that testing guidelines for hereditary cancer genetic testing in patients with prostate cancer are restrictive and may miss patients with pathogenic germline variants whose treatment and follow-up care recommendations may be changed based on their genetic test result.